Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InfiMed

This article was originally published in Start Up

Executive Summary

InfiMed is using biodegradable microspheres to release protein drugs at a steady rate, cutting down dramatically on the number of necessary injections.

You may also be interested in...



Broad, Broader, Broadest: Drug Delivery Start-Ups

Drug delivery start-ups abound, despite the harsh environment for new biopharmaceutical companies. Drug delivery deals are increasing, as are relatively highly valued acquisitions, as larger drug delivery or service companies seek to broaden their tool kits. But for companies who haven't yet proven themselves, dealmaking is difficult in a variety of ways. Credibility is tough to achieve.

Women's Health: Too early or Too Late?

As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.

EPIcyte Pharmaceutical Inc.

EPIcyte has licensed patents from the Scripps Research Institute covering new methods of human antibody production in plants that can lower costs up to 100 fold. The company is also developing proprietary products based on its technology, initially, an anti-herpes prophylactic and a contraceptive based on an anti-sperm antibody.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090068

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel